seniprutug

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
seniprutug

GtoPdb Ligand ID: 13939

Synonyms: BCD-180 | BCD180

seniprutug is an approved drug

Compound class: Antibody

Comment: Seniprutug (BCD-180) is a monoclonal antibody that targets T cell receptor beta variable 9 (TRBV9) [1]. It induces antibody-dependent cellular cytotoxicity in the target effector T cell population without causing risk of systemic immunosuppression (that would be caused by destroying T cell subsets that are responsible for essential protective functions).

Immunopharmacology Comments
Designed to inhibit the function of effector CD8+ cells that express the TRBV9 TCR, as these cells are proposed to drive inflammation and cartilage destruction in ankylosing spondylitis [1-2]. Selective targeting of this small subset of T cells spares adaptive T cell responses performed by other T cell subtypes. Seniprutug's mechanism of action offers a disease-modifying therapeutic option for this autoimmune disease.

Immunopharmacology Comments

Designed to inhibit the function of effector CD8+ cells that express the TRBV9 TCR, as these cells are proposed to drive inflammation and cartilage destruction in ankylosing spondylitis [1-2]. Selective targeting of this small subset of T cells spares adaptive T cell responses performed by other T cell subtypes. Seniprutug's mechanism of action offers a disease-modifying therapeutic option for this autoimmune disease.